Yukihiro Sanada, Koichi Mizuta, Youichi Kawano, Satoshi Egami, Makoto Hayashida, Shuji Hishikawa, Hideo Kawarasaki – 29 October 2008 – A 7‐month‐old boy with biliary atresia accompanied by situs inversus and absent inferior vena cava (IVC) underwent living‐donor liver transplantation (LDLT). Because a constriction in the recipient hepatic vein (HV) was detected during the preparation of the HV in LDLT, a dissection in the cranial direction and a total clamp of the suprahepatic IVC was performed, and the suprahepatic IVC and the graft HV were anastomosed end‐to‐end.

Alex S. Knisely, Richard J. Thompson – 29 October 2008

Gebhard Wagener, Gina Gubitosa, John Renz, Milan Kinkhabwala, Tricia Brentjens, James V. Guarrera, Jean Emond, H. Thomas Lee, Donald Landry – 29 October 2008 – Vasodilation due to impaired vascular tone is common in liver failure. Vasoconstrictor drugs are almost always required during the anhepatic phase of a liver transplant to maintain blood pressure unless venovenous bypass is employed.

Shimon Kusne – 29 October 2008

James D. Perkins – 29 October 2008

Milton J. Finegold, Rachel A. Egler, John A. Goss, R. Paul Guillerman, Saul J. Karpen, Rajesh Krishnamurthy, Christine Ann O'Mahony – 29 October 2008 – Liver tumors in childhood are rare and are typically not detected clinically until they reach a large size and often spread within the organ or metastasize. This can make surgical resection problematic, and almost all of them require extirpation for cure.

Udeme D. Ekong, Hector Melin‐Aldana, Roopa Seshadri, Joan Lokar, Dave Harris, Peter F. Whitington, Estella M. Alonso – 29 October 2008 – The factors that influence the long‐term histological outcome of transplanted liver allografts in children are not yet fully understood, and the role of surveillance biopsies in patients with normal graft function remains controversial. The aims of this study were to describe the long‐term graft histology of pediatric liver transplant recipients surviving at least 3 years and to analyze factors correlating with long‐term histological outcome.

Joseph F. Buell, Guy N. Brock – 29 October 2008

Li‐Yi Xie, Min Fan, Jia Fan, Jian Wang, Xuan‐Li Xu, Guo‐Liang Jiang – 29 October 2008

Laura Rinaldi, Marco Marietta, Mariano Alejandro Mignini, Lara Donno, Stefano Busani, Mauro Codeluppi, Michele Masetti, Massimo Girardis – 29 October 2008 – Recombinant human activated protein C (rhAPC) has been approved for use in patients with severe sepsis at high risk of death. Because of the high risk of bleeding, liver transplantation (LT) patients have been excluded from the randomized control trials that evaluated efficacy and safety of rhAPC and, thus, few data are available on the use of this drug in LT patients with severe sepsis.